Confluent, Inc. 8-K

What Happened
Confluent, Inc. (CFLT) filed an 8-K on Feb 4, 2026 to voluntarily supplement its definitive proxy (filed Jan 9, 2026) for the proposed merger with IBM (Merger Agreement dated Dec 7, 2025). The company says it denies allegations but is adding supplemental disclosures to the proxy to moot claims and reduce litigation risk. Confluent disclosed it has received 17 demand letters and that two stockholder complaints were filed in New York state court (Stewart v. Confluent, Index No. 650388/2026 on Jan 21, 2026; Kent v. Confluent, Index No. 650414/2026 on Jan 22, 2026). The special meeting to vote on the merger is scheduled for Feb 12, 2026 (live webcast, 9:00 a.m. PT).

Key Details

• Merger timeline: Merger Agreement signed Dec 7, 2025; definitive proxy filed Jan 9, 2026; special meeting set for Feb 12, 2026.
• Stock counts used in fairness work: Morgan Stanley used fully diluted shares of 353.2M outstanding, plus 17.2M options and 19.3M RSUs (management data as of Dec 5, 2025).
• Cash/valuation inputs: Morgan Stanley’s Discounted Equity Value analysis added estimated future net cash of ≈$1.5B (from management plan); its DCF analysis added Confluent net cash of ≈$890M as of Sept 30, 2025. Morgan Stanley used revenue multiples of 5.0x–8.0x (2028 revenue) and DCF terminal multiples of 12.5x–17.5x; discount rates ranged ~11.1%–12.8%.
• Litigation: 17 demand letters and two shareholder complaints allege proxy misstatements (negligent misrepresentation and concealment under NY law); Confluent denies wrongdoing and says supplemental disclosures are immaterial.

Why It Matters

• For shareholders: supplemental disclosures and pending litigation relate directly to the proxy materials voters will rely on at the Feb 12, 2026 meeting—these items could influence vote decisions.
• For deal risk and timing: additional lawsuits or demand letters could increase legal costs, create delays or procedural uncertainty even though Confluent intends the supplement to reduce that risk.
• For valuation context: Morgan Stanley’s disclosed inputs (share counts, cash, multiples, price-target range of $24–$36, median $28) show the financial assumptions behind the fairness opinion tied to the Merger.